Ellevest Inc’s Royalty Pharma RPRX Stock Holding History

Ellevest Inc’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-75	Closed	-$3K	–	1614
2021 Q3	$3K	Sell	75 -170	-69%	-$6.61K	﹤0.01%	1080
2021 Q2	$10K	Buy	+245	New	+$10.4K	﹤0.01%	761

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ellevest Inc's RPRX Position: Q4 2021 in Review

Ellevest Inc sold out of Royalty Pharma (RPRX) in Q4 2021, closing a stake of 75 shares — an estimated $3K sold.

Ellevest Inc first reported a position in RPRX in Q2 2021 and held it in 2 quarters. The position peaked at $10K in Q2 2021. 266 funds tracked by Wall St. Rank hold RPRX as of Q4 2021.

Ellevest Inc reported no remaining Royalty Pharma position as of Q4 2021 after selling out during the quarter.
Ellevest Inc sold 75 Royalty Pharma shares in Q4 2021, an estimated $3K.
Ellevest Inc first reported a position in Royalty Pharma in Q2 2021 and held it in 2 quarters.
Ellevest Inc's Royalty Pharma position peaked at $10K in Q2 2021.
266 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2021.

Based on Ellevest Inc's 13F filing for Q4 2021, filed 24 Jan 2022.